

NORTH CANCER ALLIANCE – WHAT TRIGGERS A REVIEW OF A CMG?

It is the responsibility of the tumour-specific Clinical Director to ensure CMGs are reflective of current clinical practice. The requirement for CMGs is described by the CEL 30 (2012) which notes the requirement that there is ‘a co-ordinated regional approach to their development in place’ which will ‘support a consistent approach to care delivery’.

A sample list of triggers for CMG review is available in the table to the right.



Review cycle every three years	Pathway Boards must undertake a review of CMGs every three years.
Clinical Director	With responsibility for the CMG, the Clinical Director can at any time propose a review of a CMG through the tumour-specific Pathway Board and this can be taken forward where there is consensus to do so.
Change in clinical practice	Where identified, changes in clinical practice will warrant a review of the CMG to ensure it is representative of current regional practice. Any clinician can look to trigger this through a discussion with a Clinical Director.
Regional variance	Where a variance is identified in clinical practice by members of the Pathway Board, this must trigger a CMG review to ensure clinical practice is concurrent with best practice. Please note this does not mean adopting practice of other boards / regions, but is a platform for scrutinising our own practice and ensuring CMG is representative for best patient outcomes.
Changes to SACT components of CMG	These changes occur more frequently with the introduction of new drugs and development of regional protocols. They do not always require a full review of a CMG; the SACT element can be reviewed in line with new drugs or regimens. The SACT appendix to the CMG can be approved through the processes identified, usually through the Area Drug Therapeutic Committees (ADTC). Once SACT protocols developed, these must be shared with all members of Pathway Boards and the tumour-specific Pathway Board.
Pathway Board work plan	As part of the Pathway Board actions in response to Quality Performance Indicator (QPI) results, survival analysis or any other work undertaken, this may require a review of a CMG.
National recommendation	At any time, the region may be required to undertake a review of CMGs.